Rimonim Venture Capital

Sharon Devir, PhD, and Michal Devir, MD, serve as co-founders and managing general partners, leading the firm alongside co-founder Yigal Galli. The senior team is complemented by Venture Partner Omar Massarwa and Partner Meir Rabinovitch. This compact structure points to a consensus-based investment committee driven by the founding GPs' scientific and medical backgrounds.

Rimonim invests at the seed stage in Israeli Agri-tech and FoodTech startups, targeting technologies that address global food shortages exacerbated by climate change. The firm's stated sector scope includes automation and drones, soil and crop technology, irrigation, AgBio, and supply-chain innovations. Its disclosed portfolio companies operate in areas such as gene-editing, autonomous robotics, and post-harvest shelf-life extension.

The firm explicitly identifies its strategy as Early Stage, encompassing Seed and Start-up phases. Its portfolio activity, such as backing eggXYt and Sufresca, confirms a focus on companies still in the product-development or early-commercialization stages, typical of a venture firm writing first or second institutional checks.

Rimonim presents itself as a venture capital firm with a team of managing general partners and venture partners. While the principals' names include a married couple among the founders, the firm is structured as an asset manager raising a fund, not as a single-family office vehicle.

All disclosed activity points exclusively to direct equity investments in portfolio companies, consistent with an early-stage venture capital model. There is no public evidence of fund-of-funds commitments, co-investment clubs, or SPV structures.

The firm's mandate is focused on Israel, where its entire disclosed portfolio is based. Rimonim's website emphasizes Israel's technology clusters as the sourcing ground for companies that address global agricultural challenges, but the firm itself does not claim to invest directly outside the country.

Rimonim leans on its founding partners' PhD and MD backgrounds to position the team as 'industry experts' with technical access to Israeli Agri-tech innovators. The firm markets its human capital — rather than a large platform or formal scouting network — as the primary channel for identifying companies in fields like gene-editing and autonomous agriculture.